BioSpace News Archive

JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that t

Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the company launches a new concept for patient specific immunotherapy, called Neo-X-Prime . Alligator presents the concept at the scientific congress 11th World Bispecific Summit held September 22-24, 2020 . The new concept, based on Alligator’s bispecific

With more than 90 years of cutting-edge research, design, and manufacturing experience, Swany is committed to providing the best in performance products.

Datica, a top vendor in EHR integration and cloud compliance, has been highly rated for its API-based interoperability solutions by Chilmark Research, a renowned market intelligence firm. The analysis from the report, Open APIs in Healthcare: The Future of Data Integration , recognized Datica for three critical achievements:

Select Medical Corporation, a wholly-owned subsidiary of Select Medical Holdings Corporation, announced a joint venture agreement with Rush University System for Health to manage operations of a critical illness recovery hospital, inpatient rehabilitation hospital and 63 physical therapy centers throughout the greater Chicago and Northwest Indiana region.

National Partners in Healthcare (NPH), a national healthcare organization delivering best in class anesthesiology services, announced today that Rocky Mountain Anesthesiology (Rocky) has joined NPH.

Chesapeake Urology, an affiliate of United Urology Group, recently welcomed three new physicians to its growing team of specialists and general urologists.

The following is attributed to Jeffrey Shuren, M.D., director of FDA’s Center for Devices and Radiological Health [24-September-2020] SILVER SPRING, Md. , Sept. 24, 2020 /PRNewswire/ -- Part of our role in protecting patients is to regularly evaluate, monitor and update scientific evidence on the risks from medical devices—including issues related to the materials use

Abivax today announces its 2020 half-year financial results, as of June 30, 2020, and provides an update on its pipeline progress.

Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has initiated its first Phase 3 study to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. The trial is being conducted in the United Kingdom (UK), in partnership with the UK Government’s Vaccines Taskforce, and is expected to enroll